Use cases
PSC-derived brain organoids—not 2D primary neurons and not glioma PDO.
| Use | Fit | Readout | Notes |
|---|---|---|---|
| Human PSC cerebral organoids for development / disease | Recommended | Neuroepithelium, laminar features, disease phenotypes[1][2] | Lancaster workflow fits a standard TC room; windows need pilots. |
| 2D neural-progenitor contrast after dual-SMAD | Contrast | PAX6 / SOX2 positivity[3] | 2D contrast helps tell whether 3D failure is induction itself. |
| Primary 2D neurons or glioma spheroids as “brain organoids” | Do not mix | Adherent networks / spheroid diameter | Not self-organized PSC cerebral organoids. |
In one line
PSC → ULA EB → neural induction ± dual-SMAD → BME embed → Neurobasal/B-27/N-2 expand → SOX2/PAX6/MAP2 QC.
Protocol overview
- Confirm PSC/iPSC pluripotency and mycoplasma clearance; ethics and line licenses in place
- Seed ULA 96-well plates for EBs; brief Y-27632
- Neural induction: dual-SMAD (Noggin or LDN193189 + SB431542) or Lancaster default; optional CHIR / FGF2 windows[[1]][[3]]
- Embed EBs in BME droplets; move to spinning or static expansion
- Feed Neurobasal ± DMEM/F12 + B-27 + N-2; log lots
- From weeks 2–4 score ventricle-like neuroepithelium; SOX2 / PAX6 / Nestin
- Longer culture for MAP2 / βIII-Tubulin; add patterning factors only when regionalization is required
- Disease modeling and drugs after morphology stabilizes; in vivo take is a transplant SOP